These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9250283)

  • 21. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon].
    Porcaro G; Sannino C; Mastroianni M; Ciavattone A; Bartiromo D; Nascia S
    Minerva Med; 2000; 91(7-8):141-5. PubMed ID: 11155462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation.
    Van Thiel DH; Molloy PJ; Friedlander L; Kania RJ; Fagiuoli S; Caraceni P; Wright HI; Zuhdi N
    Hepatogastroenterology; 1995; 42(6):900-6. PubMed ID: 8847043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels.
    Kiso S; Kawata S; Imai Y; Tamura S; Inui Y; Ito N; Matsuzawa Y
    J Gastroenterol; 1996 Feb; 31(1):75-80. PubMed ID: 8808432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interferon alfa in the treatment of chronic hepatitis C: course of 24 versus 48 weeks. Results of a randomized trial].
    Fassio E; Viudez P; Guma C; Landeira G; Fernandez N; Alvarez E
    Acta Gastroenterol Latinoam; 1996; 26(3):149-53. PubMed ID: 9180949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.
    Banner BF; Barton AL; Cable EE; Smith L; Bonkovsky HL
    Mod Pathol; 1995 Apr; 8(3):232-8. PubMed ID: 7542385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
    Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
    Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
    Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
    Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Yoshii O; Matsumoto T; Kuwabara N; Mitamura K
    Am J Gastroenterol; 1996 Oct; 91(10):2144-9. PubMed ID: 8855738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.